220033-99-8

Upstream product

• 259726-51-7 (R)-2-[(2R,3S,5R,6S)-3-Benzyloxycarbonylmethoxy-6-(tert-butoxycarbonylamino-methyl)-5-isobutoxy-tetrahydro-pyran-2-yl]-propionic acid tert-butyl ester 
• 100-39-0 benzyl bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 259726-52-8 (R)-2-((2R,3S,5R,6S)-6-Aminomethyl-3-benzyloxycarbonylmethoxy-5-isobutoxy-tetrahydro-pyran-2-yl)-propionic acid 

Downstream Products

• 220034-00-4 (S)-3-{(R)-2-[(2R,3S,5R,6S)-3-Benzyloxycarbonylmethoxy-6-(tert-butoxycarbonylamino-methyl)-5-isobutoxy-tetrahydro-pyran-2-yl]-propionylamino}-N-((S)-1-benzyloxycarbonyl-2-phenyl-ethyl)-succinamic acid benzyl ester 
• 259726-54-0 (S)-3-((R)-2-{(2R,3S,5R,6S)-6-[((S)-2-Acetylamino-3-phenyl-propionylamino)-methyl]-3-benzyloxycarbonylmethoxy-5-isobutoxy-tetrahydro-pyran-2-yl}-propionylamino)-N-((S)-1-benzyloxycarbonyl-2-phenyl-ethyl)-succinamic acid benzyl ester 

Relevant academic research and scientific papers

Design and synthesis of a tetrahydropyran-based inhibitor of mammalian ribonucleotide reductase

A tetrahydropyran-based inhibitor (2) of mammalian ribonucleotide reductase (mRR) has been designed and synthesized based on the heptapeptide, N-AcFTLDADF (1), corresponding to the C-terminus of the R2 subunit of mRR. Inhibition studies revealed that 2 is indeed a competent inhibitor, albeit less potent than 1.